We report a comparative evaluation of three different laboratory methods for screening large numbers of mouthwash DNA samples for common cystic fibrosis mutations. Sensitivity, specificity, and costs of ARMS (allele refractory mutation detection system), dot blotting, and a deletion/digest/PAGE method (multiplex PCR of exons 10 and 11, digest with HincII followed by polyacrylamide gel electrophoresis (PAGE)) were assessed. ARMS was the most reliable and sensitive method and so was considered more suitable than the cheaper deletion/digest/ PAGE. As well as being less reliable than ARMS, the dot blotting method assessed was considerably more costly. ARMS was the best laboratory method for CF screening tested.
Carrier testing for cystic fibrosis ' Standard methods of CF mutation analysis include deletion detection using polyacrylamide gel electrophoresis (PAGE) of PCR product (for example, AF508 and AI507), restriction enzyme digestion of PCR product (for example, G551D , R553X, 621 + 1(G-.T)), and probing of PCR product with labelled allele specific oligonucleotides (ASOs) (for example, G542X).'247 Recently, an ARMS (amplification refractory mutation system) multiplex PCR technique has come into widespread use in the UK, namely the Cellmark Diagnostics CF Mutation Detection Kit. 8 Population carrier screening programmes and routine diagnostic laboratories would benefit from a mutation detection system that uses a minimal amount of labour and is technically reliable, sensitive, and specific without being too costly. Methods that detect more than one mutation simultaneously (multiplexing) are more efficient in use of labour and reagents. Such multiplex mutation detection can be performed by dot blotting methods, by a combination of deletion detection and restriction enzyme digest, or by using an ARMS system.8-'0
We have performed a comparative assessment of the technical reliability, sensitivity, specificity, and costs of three types of mutation detection to find the best method for population CF screening.
Methods
The Cellmark ARMS system tests simultaneously for the mutations AF508, G551D, G542X, and 621 + 1(G--T).5 PCR is performed in two tubes, one tube containing mutation specific primers for G551D, G542X, and normal site specific primers for AF508 and 621 + 1(G-+T), the second containing mutation specific primers for AF508 and 621 + 1(G-4T) and normal site specific primers for G55 1D and G542X. Test DNA (5 gl mouthwash preparation) is added to each of these two tubes. After addition of oil the tubes are placed in the PCR block. Diluted Taq polymerase enzyme is added to each tube after two minutes ("hot start"), and then the PCR cycle is started. Products are detected by Nusieve agarose gel electrophoresis (fig 1) .
Various multiplex dot blotting systems have been described. They use different techniques to allow hybridisation with several oligonucleotides to occur under the same conditions by using T tails on oligonucleotide probes, the addition of tetramethylammonium chloride (TMAC), or differing lengths of oligonucleotide.9"' The reverse dot blot technique is usually used, with PCR product from each exon under study being labelled by incorporation in a multiplex PCR reaction. We chose to evaluate dot blotting by using the Inno-LiPA CF2 kit as an example (Innogenetics).9 This kit detects the mutations AF508, AI507, G551D, G542X, N1303K, W1282Xm 1717-1,G-A, and R553X.4 12"1 Mouthwash DNA preparation (5 p1) and Taq polymerase are added to the PCR reagents provided, with biotin dUTP incorporated into PCR product as a label. After thermal cycling, PCR product from each patient is incubated with a membrane based strip, to which oligonucleotides of differing lengths have been bound. Two oligonucleotides are used for each mutation, one for the normal and one for the mutation sequence. Hybridisation is performed in a trough provided by the manufacturer. Streptavidin labelled alkaline phosphatase is then added which binds to the biotinylated PCR product. Incubation with a BCIP/NBT (bromochoro-indolyl phosphate/ nitroblue tetrazolium) chromogen results in a This system was assessed by testing samples from the 55 carriers detected above, 16 partners' samples (previously tested negative), and 19 samples from affected persons. All these samples had been previously tested by ARMS. Testing was performed according to the manufacturer's instructions.
DELETION/DIGEST/PAGE METHOD
This method was used to test DNA from 59 carriers, 58 partners (previously tested negative), and 64 persons affected by CF, for AF508, G551D, AI507, and R553X. These samples had previously been tested using the other two methods. We are grateful to our colleagues at the Human Genetics Unit in Edinburgh for giving us further details of their published method. 10 
COSTING
The costs of consumables for each method of testing included the cost of unsupplied reagents required in addition to those supplied in the kits. As the Cellmark system is not commercially available, the anticipated cost was obtained from the manufacturer (£10 to £14 per test, so £12 used in calculations). Time sheets were used to estimate labour costs for each method (only the labour specifically relevant to this project counted). Employment costs of £12.08 ($17.73) per hour were used (cost of a grade B clinical scientist, spine point 9). Reagent and labour costs were calculated for five batches of each type of test. Record keeping time and reading of gels was included in our assessment. Mean cost for 100 samples was then calculated to allow comparability. Note that the optimum number of tests per batch varies for each method (table). US dollar ($) equivalent prices were calculated using an exchange rate of $1.4679 to the pound (£) sterling.
In addition, the costs of producing and posting reports were estimated (secretarial time was were not required. If running a prenatal screening service, holiday cover is essential for all staff. This is accounted for in the costing assuming that salaries of replacements are the same as those of the regular staff.
The cost of commercial CF kits reflect high licensing charges for the use of PCR and the CF gene (Toronto Sick Children's Hospital). The position of individual laboratories regarding these charges is as yet unclear in the UK, although it seems likely that "home made" systems will prove much cheaper. It may be that the high licensing charges will limit the availability of carrier testing.
